Clinical Significance of Onycholysis

Primary Clinical Implications

Taxane chemotherapy causes onycholysis in 34.9-43.7% of patients, making it one of the most common chemotherapy-related adverse events 1, 2
Severe onycholysis occurs almost exclusively with taxanes, though mild-to-moderate cases occur with capecitabine, etoposide, cytarabine, cyclophosphamide, doxorubicin, and targeted therapies (mTOR inhibitors, EGFR inhibitors, MEK inhibitors) 5, 6
The condition is dose-related and cumulative, increasing with number of treatment cycles and more common with weekly paclitaxel regimens 3, 4
Lesions can become severely painful and functionally disabling, affecting quality of life sufficiently to warrant treatment changes 3, 4

Once separation occurs, the onycholytic space becomes vulnerable to secondary infections that can progress to painful subungual abscesses, requiring urgent intervention 1, 3
Chronic onycholysis leads to nail bed keratinization and persistent subungual hyperkeratosis, potentially becoming permanent if not addressed early 3
Pain occurs from acute trauma, progression of detachment, or development of subungual hematoma/abscess with purulent discharge 3, 4

Fingernails are more commonly affected than toenails in taxane-related onycholysis, though involvement may be diffuse 1, 3
The onycholytic portion becomes opaque, losing transparency, and can appear black, white, or brown-red 3, 4
Nail lesions appear after several weeks of treatment due to slow nail plate growth rate 1, 3
Taxane-related onycholysis may be associated with PATEO syndrome (inflammatory erythema of dorsal hands, perimalleolar or Achilles areas) 3, 4

Direct cytotoxic damage to nail bed epithelium causing epidermolysis and loss of nail plate adhesion 3, 4
Anti-angiogenic activity of taxanes affecting nail bed vasculature 3
Neurotropic effects on peripheral nerves, with nerve integrity being a substantial factor in developing nail alterations 3, 4
Increased systemic exposure to cremophor vehicle (paclitaxel solvent) may explain higher incidence with weekly regimens 3, 4

Failure to promote nail reattachment early can result in permanent onycholysis due to nail bed keratinization 3
In taxane-related cases, removal of the nail plate may be necessary for severe/painful lesions or when associated with pressure hematoma or subungual abscess 3, 4

Beyond physical morbidity, onycholysis causes significant psychosocial distress and functional impairment 3, 8
Cosmetic concerns lead to embarrassment and social avoidance 8
Functional disability affects activities of daily living 3, 4
In cancer patients, the condition can necessitate treatment interruption or discontinuation, potentially compromising oncologic outcomes 3, 4